Search

Your search keyword '"Lin, Yimou"' showing total 14 results
Start Over Author "Lin, Yimou"
14 results on '"Lin, Yimou"'

2. Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study

Author

Guo, Zhiyong, Liu, Yao, Ling, Qi, Xu, Leibo, Wang, Tielong, Zhu, Jiaxing, Lin, Yimou, Lu, Xinjun, Qu, Wei, Zhang, Fan, Zhu, Zhijun, Zhang, Jian, Jia, Zehua, Zeng, Ping, Wang, Wenjing, Sun, Qiang, Luo, Qijie, Hu, Zemin, Zheng, Zhouying, Jia, Yingbin, Li, Jian, Zheng, Yujian, Wang, Mengchao, Wang, Shaoping, Han, Zemin, Yu, Sheng, Li, Chuanjiang, Zhang, Shuhua, Xiong, Jun, Deng, Feiwen, Liu, Ying, Chen, Huanwei, Wang, Yanfeng, Li, Ling, Liang, Wenjin, Schlegel, Andrea, Nashan, Björn, Liu, Chao, Zheng, Shusen, and He, Xiaoshun

Published
2024
Full Text
View/download PDF

5. Serum Exosome-Derived piRNAs Could Be Promising Biomarkers for HCC Diagnosis

Author

Rui,Tao, Wang,Kai, Xiang,Aizhai, Guo,Jufeng, Tang,Ning, Jin,Xin, Lin,Yimou, Liu,Jian, and Zhang,Xiaobing

Subjects
Biomaterials, International Journal of Nanomedicine, Organic Chemistry, Drug Discovery, Biophysics, Pharmaceutical Science, Bioengineering, General Medicine
Abstract

Tao Rui,1,2 Kai Wang,1,2 Aizhai Xiang,1 Jufeng Guo,1 Ning Tang,1 Xin Jin,1 Yimou Lin,3 Jian Liu,1 Xiaobing Zhang1,2 1Department of Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China; 2Key Laboratory of Integrated Oncology and Intelligent Medicine of ZheJiang Province, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China; 3Department of Surgery, Collaborative Innovation Center for the Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University Hangzhou, Hangzhou, 310003, People’s Republic of ChinaCorrespondence: Tao Rui; Xiaobing Zhang, Email 11818248@zju.edu.cn; 11818341@zju.edu.cnBackground: Serum exosome-based liquid biopsy has significant advantages for screening and diagnosing hepatocellular carcinoma (HCC). P-element-induced wimpy testis (PIWI)-interacting RNAs (piRNAs) are novel small silencing RNAs that have been identified to function in cancer-related signalling pathways. However, studies on the presence of piRNAs in serum exosomes from HCC patients and their diagnostic values in HCC are not well reported. Our aim is to validate serum exosome-derived piRNAs as the valuable component of liquid biopsy for diagnosing HCC.Methods: We used small RNA (sRNA) sequencing to profile piRNAs from serum exosomes and describe the base distribution characteristics of serum exosome-derived piRNAs. Serum exosomes from 125 HCC patients and 44 nontumor donors were included in this study.Results: We found that piRNAs were components of serum exosomes from HCC patients. A total of 253 differentially expressed serum exosome-derived piRNAs were screened from HCC compared with the piRNAs from nontumor donors. Serum exosome-derived piRNAs from HCC displayed a distinctive base distribution. To further confirm the potential diagnostic value of serum exosome-derived piRNAs in HCC, we detected the levels of the top 5 upregulated piRNAs in our Chinese cohort. The training set and validation set both showed that all 5 piRNAs were dramatically increased in the serum exosomes from HCC compared with the piRNAs from non-tumour donors. The piRNAs could strongly identify HCC patients from non-tumour donors according to the area under the receiver operating characteristic (AUROC) model. Additionally, the piRNAs could also present significant values for the diagnosis of HCC with low tumour burden.Conclusion: piRNAs enriched the components of serum exosomes from HCC and could serve as promising biomarkers for HCC diagnosis.Keywords: biomarker, exosome, sRNA-seq, HCC, piRNA

Published
2023

14. Assessing Donor Liver Quality and Restoring Graft Function in the Era of Extended Criteria Donors.

Author

Lin Y, Huang H, Chen L, Chen R, Liu J, Zheng S, and Ling Q

Abstract

Liver transplantation (LT) is the final treatment option for patients with end-stage liver disease. The increasing donor shortage results in the wide usage of grafts from extended criteria donors across the world. Using such grafts is associated with the elevated incidences of post-transplant complications including initial nonfunction and ischemic biliary tract diseases, which significantly reduce recipient survival. Although several clinical factors have been demonstrated to impact donor liver quality, accurate, comprehensive, and effective assessment systems to guide decision-making for organ usage, restoration or discard are lacking. In addition, the development of biochemical technologies and bioinformatic analysis in recent years helps us better understand graft injury during the perioperative period and find potential ways to restore graft function. Moreover, such advances reveal the molecular profiles of grafts or perfusate that are susceptible to poor graft function and provide insight into finding novel biomarkers for graft quality assessment. Focusing on donors and grafts, we updated potential biomarkers in donor blood, liver tissue, or perfusates that predict graft quality following LT, and summarized strategies for restoring graft function in the era of extended criteria donors. In this review, we also discuss the advantages and drawbacks of these potential biomarkers and offer suggestions for future research., Competing Interests: The authors have no conflict of interests related to this publication., (© 2023 Authors.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results